ABSTRACT
OBJECTIVE@#To assess the effect and safety of Hydroxysafflor Yellow A for Injection (HSYAI) in treating patients with acute ischemic stroke (AIS) and blood stasis syndrome (BSS).@*METHODS@#A multicenter, randomized, double-blind, multiple-dose, active-controlled phase II trial was conducted at 9 centers in China from July 2013 to September 2015. Patients with moderate or severe AIS and BSS were randomly assigned to low-, medium-, high-dose HSYAI groups (25, 50 and 70 mg/d HSYAI by intravenous infusion, respectively), and a control group (Dengzhan Xixin Injection (, DZXXI) 30 mL/d by intravenous infusion), for 14 consecutive days. The primary outcome was the Modified Rankin Scale (mRS) score ⩽1 at days 90 after treatment. The secondary outcomes included the National Institute of Health Stroke Scale (NIHSS) score ⩽1, Barthel Index (BI) score ⩾95, and BSS score reduced ⩾30% from baseline at days 14, 30, 60, and 90 after treatment. The safety outcomes included any adverse events during 90 days after treatment.@*RESULTS@#Of the 266 patients included in the effectiveness analysis, 66, 67, 65 and 68 cases were in the low-, medium-, and high-dose HSYAI and control groups, respectively. The proportions of patients in the medium- and high-dose HSYAI groups with mRS score ⩽1 at days 90 after treatment were significantly larger than the control group (P0.05).@*CONCLUSIONS@#HSYAI was safe and well-tolerated at all doses for treating AIS patients with BSS. The medium (50 mg/d) or high dose (75 mg/d) might be the optimal dose for a phase III trial. (Registration No. ChiCTR-2000029608).
ABSTRACT
Acupuncture and moxibustion has a wealth of experience in the prevention and control of epidemic disease since ancient times, which was used for all kinds of acute infectious diseases in modern times and its efficacy has been clearly and reliably reported. This article proposes the theoretical feasibility and reliability of acupuncture and moxibustion interventional prevention and treatment by discussing the recognition of coronavirus disease 2019 (COVID-19) from the perspective of acupuncture and moxibustion. The unique "acupuncture and moxibustion program" for COVID-19 is presented including treatment in different stages, selecting acupoints by distinguishing meridians, applying needle technique by various methods. The article also proposes a new understanding of acupuncture and moxibustion at related acupoints on the surface of the body that can directly affect the "" to treat the disease.
Subject(s)
Humans , Acupuncture Therapy , Betacoronavirus , Coronavirus Infections , Therapeutics , Moxibustion , Pandemics , Pneumonia, Viral , Therapeutics , Reproducibility of ResultsABSTRACT
Objective To compare the clinical efficacy and safety of electroacupuncture and hormone replacement therapy (HRT) on the treatment of perimenopausal syndrome (PMS). Methods Clinical randomized controlled trial literature about electroacupuncture and HRT for the treatment of PMS in CNKI, Wanfang database, CBM, Chongqing Weipu, PubMed and Cochrane Library from establishment of the databases to 28thof January 2017 was retrieved by computers. Two researchers screened out data and extracted materials quality. Qualities of the literature were assessed by relevant standards in the Cochrane Handbook 5.1.0. Meta-analysis was conducted with RevMan5.3 software. Results 6 articles with 457 participants met the inclusion criteria and were included in this study. Meta-analysis showed that during the treatment or the follow-up period of 6 months, there was no significant difference in the improvement of serum E2and Kupperman scores between the electroacupuncture and HRT. With the prolongation of treatment time, electroacupuncture showed superiority over HRT in depressing the level of serum FSH [MD=-5.93, 95%CI (-9.90, -1.96), P=0.003], with statistical significance. During the treatment period, the electroacupuncture group had fewer adverse reactions. Conclusion Electroacupuncture can effectively treat PMS, with similar efficacy as HRT, and with good safety, which can provide references for clinic. However, the quality of included studies is generally low, yet more large sample, multicenter, high-quality clinical RCTs are needed for further validation.
ABSTRACT
<p><b>BACKGROUND</b>Polymorphisms of microRNA (miRNA), as a novel mechanism, are closely associated with disease states by interfering with miRNA function. Direct correlations have been identified between single-nucleotide polymorphisms (SNPs) in miRNA, but the effect on type 2 diabetes mellitus (T2DM) onset among Chinese population remains unclear. Therefore, the aim of this study was to identify correlations between common SNPs in miR-27a, miR-146a, and miR-124a with T2DM among a Chinese population, as well as to explore diabetic pathological mechanisms and the impact of environmental factors.</p><p><b>METHODS</b>SNPscan technology was used to genotype 995 patients newly diagnosed with T2DM and 967 controls. Logistic regression analysis was performed to compare mutation frequencies between cases and controls.</p><p><b>RESULTS</b>We found no significant correlations between all genotypes of these miRNAs and T2DM in our research. However, stratification analysis identified a lower risk of T2DM associated with the rs531564GC genotype among younger subjects (age < 45 years) (adjusted P = 0.043; odds ratio [OR] = 0.73; 95% confidence interval [CI] = 0.54-0.99). Furthermore, the rs895819CC genotype in overweight people (24 ≤ body mass index [BMI] < 28) was significantly associated with an increased risk of T2DM (adjusted P = 0.042; OR = 1.73; 95% CI = 1.02-2.94), while the rs2910164 genotype in miR-146a was not significantly correlated with T2DM. The genetic risk score was calculated based on the number of risk alleles of the three SNPs and was found to be correlated to total cholesterol (adjusted P = 0.021).</p><p><b>CONCLUSIONS</b>The rs531564GC genotype acted as a protective factor to decrease the risk of T2DM in younger subjects (age < 45 years), while the presence of the rs895819CC genotype increased the risk of illness among overweight subjects (24 ≤ BMI < 28 kg/m 2 ). The presence of SNPs in miRNA might promote disease by affecting miRNA expression and gene function. Thus, miRNA mimics or inhibitors that directly regulate miRNA expression present novel and promising therapeutic targets.</p>